Glioblastoma Clinical Trials in Washington D.C., District of Columbia

6 studies are recruiting for glioblastoma in Washington D.C., District of Columbia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Targeted Pediatric High-Grade Glioma Therapy

   The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular profiling will decide if patients are eligible to participate in a subsequent treatment-based clinical …

   Stage

   Not phased

   Ages

   1 to 39

   Site

   Children's National Medical Center, Washington D.C., District of Columbia

   Locations

   22 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT05839379 on ClinicalTrials.gov

2. EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

   This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Gliobla…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   MedStar Georgetown University Hospital, Washington D.C., District of Columbia

   Locations

   102 in total

   Run by

   NovoCure GmbH

   See if you can join NCT06556563 on ClinicalTrials.gov

3. Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

   The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the safety of lorlatinib when given with chemotherapy or after radiation therapy.

   Stage

   EARLY_Phase 1

   Ages

   1 to 21

   Site

   Children's National Medical Center, Washington D.C., District of Columbia

   Locations

   18 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT06333899 on ClinicalTrials.gov

4. ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

   This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other recurrent primary malignant CNS tumors. ONC206 is a recently discovered compo…

   Stage

   Phase 1

   Ages

   2 to 21

   Site

   Children's National Hospital, Washington D.C., District of Columbia

   Locations

   7 in total

   Run by

   Sabine Mueller, MD, PhD

   See if you can join NCT04732065 on ClinicalTrials.gov

5. Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

   The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target or 2) ribociclib …

   Stage

   Phase 2

   Ages

   1 to 39

   Site

   Children's National Medical Center, Washington D.C., District of Columbia

   Locations

   20 in total

   Run by

   Nationwide Children's Hospital

   See if you can join NCT05843253 on ClinicalTrials.gov

6. Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas

   The objective of this study is to assess the tolerability, safety, and efficacy of Liposomal Curcumin (LC) in combination with radiotherapy (RT) and Temozolomide (TMZ) in patients with newly diagnosed High-Grade Gliomas (HGG).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sibley Memorial Hospital, Washington D.C., District of Columbia

   Locations

   2 in total

   Run by

   SignPath Pharma, Inc.

   See if you can join NCT05768919 on ClinicalTrials.gov